Mitsubishi Tanabe hit by new suspension over quality control worries
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma (MTP) has been ordered to suspend operations at a production plant in Japan for 10 days in relation to product quality control problems at the site identified earlier this year.